Gene Therapy Market accounted
for $584 million in 2016, and is estimated to reach $4,402 million by 2023,
registering a CAGR of 33.3% from 2017 to 2023. North America is the highest
contributor in the gene therapy market in 2016; however, Asia-Pacific is
expected to witness the highest growth rate during the forecast period.
Gene therapies are promising therapies
applicable to a broad range of diseases; their aim is to radically treat the
causes of the diseases instead of only relieving the symptoms. They may be
effective on a wide range of previously untreated diseases, such as
hematological, ocular, neurodegenerative diseases, and several cancers. For
example, adeno-associated AAV2 vectors carrying the therapeutic gene (RPE65)
intra-retinal injection resulted in improved vision for people with Lebers
Congenital Amaurosis. Gene therapies can be applied either in combination with
cell products and through an ex vivo treatment mode (e.g. Strimvelis), or
directly administered in vitro (e.g. Glybera). Several vectors present
clinically relevant options, including adenovirus (AV), adeno-associated virus
(AAV), and lentivirus.
Download PDF Report Sample with statistical info
@ https://www.alliedmarketresearch.com/request-sample/2841
The key companies profiled in the report include
Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc.,
Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies
Corporation, Oxford BioMedica, and NewLink Genetics Corp.
Other prominent players in the value chain include
Amgen, Epeius Biotechnologies, Abeona Therapeutics, Sanofi, UniQure, Juno
Therapeutics, Adaptimmune, Celgene, and Advantagene.
The increase in funding for R&D activities
pertaining to gene therapy and increase in awareness regarding gene therapy are
the major factors that drive the market growth. In addition, increase in
government support, ethical acceptance of gene therapy for cancer treatment,
and rise in prevalence of cancer can fuel the growth of the gene therapy
market. However, high cost associated with the treatment and unwanted immune
responses are expected to hamper the market growth.
Among the vector type, viral vectors contribute
to the largest share in 2016, and estimated to retain the same trend during the
forecast period. Non-viral vector is anticipated to be a lucrative market due
to the technological advancement of these vectors with positive results for
these therapies during the preclinical and clinical trials for the treatment of
various diseases.
Among the gene type, antigen dominates the
overall market accounting for two-ninths of the total share in 2016. Among the
applications, oncological disorders is the largest contributor towards the
market growth.
In 2016, North America accounted for maximum
contribution to the total revenue generated, owing to the high prevalence rate
of cancer, presence of high disposable income, and high funding for R&D
activities associated with gene therapy. However, Asia-Pacific is expected to
witness the highest CAGR during the analysis period, attributable to rise in
incidence rate of cancer, increase in government initiative to improve healthcare
infrastructure, and rise in healthcare expenditure.
Key Findings of
the Gene Therapy Market:
- Non-viral vectors is projected to grow at
the highest rate during the analysis period.
- Oncological disorders segment generated the
highest revenue, and is expected to continue its dominance in future.
- North America dominated global gene therapy
market in 2016, and is projected to continue its dominance in future.
- China is expected to grow highest in the
Asia-Pacific region during the forecast period.
- Antigen was the largest contributor among
the gene type segments.
No comments:
Post a Comment